News|Articles|January 22, 2026
De-Risking FIH: Integrated Strategies for Rapid Proof-of-Concept
Author(s)Quotient Sciences
The transition from preclinical to clinical testing is a pivotal moment in drug development. It’s also one of the most challenging development milestones, beset by unknown risks, unexpected data, and potential regulatory hurdles to overcome. In this article, Quotient Sciences experts discuss how proper planning can avoid missteps in first-in-human studies, looking at trial design, CMC, and regulatory considerations.
Related Content
Trending on Applied Clinical Trials Online
1
Study Quantifies Financial Return of Risk-Based Quality Management in Oncology Trials
2
FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development
3
ACT Brief: CRO Partnership in Program Recruitment, Psychedelic Trial Design Guidance, and Breast Cancer Pathway Inhibitor
4
Making Communications Resonate: Wherever People Are, In Their Own Words
5